Chinese healthcare investment firm Sunland Fund has raised a new vehicle to continue its focus on early and growth-stage startups in the fields of medical devices, biotechnology, and innovative drug production, said the company in a recent statement.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
